GeneDx Holdings (WGS) Consolidated Net Income (2020 - 2026)

GeneDx Holdings (WGS) has reported Consolidated Net Income for 7 consecutive years, with -$63.3 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Consolidated Net Income fell 869.81% year-over-year to -$63.3 million; the TTM figure through Mar 2026 stood at -$77.8 million (down 101.74% YoY), while the FY2025 annual figure was -$21.0 million, up 59.8% from the prior year.
• Consolidated Net Income eased to -$63.3 million in Q1 2026 per WGS's latest filing, from -$17.7 million in the prior quarter.
• Across five years, Consolidated Net Income topped out at $10.8 million in Q2 2025 and bottomed at -$308.7 million in Q4 2022.
• Historically, Consolidated Net Income has averaged -$50.7 million across 5 years, with a median of -$29.2 million in 2024.
• Annual changes were most pronounced in 2025 — Consolidated Net Income soared 137.06% — and 2026, when it tumbled 869.81%.
• GeneDx Holdings' Consolidated Net Income stood at -$308.7 million in 2022, then soared by 91.66% to -$25.8 million in 2023, then jumped by 121.19% to $5.5 million in 2024, then tumbled by 423.73% to -$17.7 million in 2025, then sank by 258.42% to -$63.3 million in 2026.
• Business Quant data shows WGS's Consolidated Net Income at -$63.3 million in Q1 2026, -$17.7 million in Q4 2025, and -$7.6 million in Q3 2025.